Post-transplant Flotetuzumab for AML

Clinical trial NCT05506956 · COMPLETED

Trial details

NCT number: NCT05506956
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute

Start date: 2022-10-20
Primary completion: 2024-06-18
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.